{
  "positions": [
    {
      "ticker": "OMER",
      "status": "OPEN",
      "play_type": "Standard",
      "is_phase3_sequential": false,
      "category": "Biotech",
      "position": {
        "strike": 5.0,
        "expiration": "2026-02-20",
        "expiration_display": "Feb 20, 2026",
        "option_type": "CALL",
        "quantity": 10
      },
      "prices": {
        "entry": 1.91,
        "current": 0.805,
        "stock_price": 12.49,
        "break_even": 6.91,
        "max_buy": 2.1,
        "pnl_pct": -57.9
      },
      "entry_zone": {
        "zone": "excellent",
        "color": "green",
        "message": "Down 57.9% from entry - better value",
        "pct_from_entry": -57.85340314136125
      },
      "enr": {
        "enr": 1747.4,
        "win_prob": 85.0,
        "enr_zone": {
          "zone": "good",
          "color": "green",
          "message": "Strong expected return"
        },
        "is_live": true
      },
      "cont": {
        "score": 70,
        "rating": "MODERATE",
        "display": "Moderate"
      },
      "catalyst": {
        "date": "2025-12-24",
        "date_display": "Dec 24, 2025",
        "event": "PDUFA APPROVED",
        "drug": "Narsoplimab/Yartemlia - TA-TMA (FDA APPROVED Dec 24, 2025)",
        "days_to_catalyst": -31
      },
      "timing": {
        "days_to_expiry": 27,
        "entry_date": "2025-12-31 07:14:59"
      },
      "thesis": {
        "drug_name": "Narsoplimab/Yartemlia - TA-TMA (FDA APPROVED Dec 24, 2025)",
        "indication": "PDUFA APPROVED",
        "highlights": [],
        "risks": [],
        "is_first_in_class": null,
        "is_orphan": null,
        "is_fast_track": null,
        "short_interest": null
      },
      "oi": {
        "current": 0,
        "change_1d": 0,
        "change_5d": 0,
        "trend": "unknown"
      },
      "last_updated": "2026-01-23T20:35:49.257829"
    },
    {
      "ticker": "RGNX",
      "status": "OPEN",
      "play_type": "Standard",
      "is_phase3_sequential": false,
      "category": "Biotech",
      "position": {
        "strike": 12.5,
        "expiration": "2026-04-17",
        "expiration_display": "Apr 17, 2026",
        "option_type": "CALL",
        "quantity": 20
      },
      "prices": {
        "entry": 4.325,
        "current": 0.275,
        "stock_price": 14.56,
        "break_even": 16.825,
        "max_buy": 4.76,
        "pnl_pct": -93.6
      },
      "entry_zone": {
        "zone": "excellent",
        "color": "green",
        "message": "Down 93.6% from entry - better value",
        "pct_from_entry": -93.64161849710982
      },
      "enr": {
        "enr": 4636.0,
        "win_prob": 95.0,
        "enr_zone": {
          "zone": "good",
          "color": "green",
          "message": "Strong expected return"
        },
        "is_live": true
      },
      "cont": {
        "score": 65,
        "rating": "MODERATE",
        "display": "Moderate"
      },
      "catalyst": {
        "date": "2026-02-08",
        "date_display": "Feb 08, 2026",
        "event": "PDUFA",
        "drug": "RGX-121 (clemidsogene lanparvovec) - Hunter Syndrome (MPS II)",
        "days_to_catalyst": 15
      },
      "timing": {
        "days_to_expiry": 83,
        "entry_date": "2025-12-31 07:15:01"
      },
      "thesis": {
        "drug_name": "RGX-121 (clemidsogene lanparvovec) - Hunter Syndrome (MPS II)",
        "indication": "PDUFA",
        "highlights": [
          "RGNX presents a legitimate high-probability approval opportunity for RGX-121, a first-in-class gene therapy for Hunter syndrome. The regulatory pathway is clean: FDA inspections complete with zero observations, no safety concerns raised, and accelerated approval alignment. The PRV optionality provid..."
        ],
        "risks": [
          "No options meet 140% ENR threshold - paying 30-50% premium over fair value",
          "28% run-up suggests approval partially priced; limited upside vs. downside",
          "Denali competition (DNL310 PDUFA April 5) creates binary outcome for market share"
        ],
        "is_first_in_class": 1,
        "is_orphan": 1,
        "is_fast_track": 1,
        "short_interest": null
      },
      "oi": {
        "current": 0,
        "change_1d": 0,
        "change_5d": 0,
        "trend": "unknown"
      },
      "last_updated": "2026-01-23T20:35:49.296353"
    },
    {
      "ticker": "RGNX",
      "status": "OPEN",
      "play_type": "Standard",
      "is_phase3_sequential": false,
      "category": "Biotech",
      "position": {
        "strike": 15.0,
        "expiration": "2026-04-17",
        "expiration_display": "Apr 17, 2026",
        "option_type": "CALL",
        "quantity": 20
      },
      "prices": {
        "entry": 4.6,
        "current": 0.2125,
        "stock_price": 14.56,
        "break_even": 19.6,
        "max_buy": 5.06,
        "pnl_pct": -95.4
      },
      "entry_zone": {
        "zone": "excellent",
        "color": "green",
        "message": "Down 95.4% from entry - better value",
        "pct_from_entry": -95.38043478260869
      },
      "enr": {
        "enr": 4911.1,
        "win_prob": 95.0,
        "enr_zone": {
          "zone": "good",
          "color": "green",
          "message": "Strong expected return"
        },
        "is_live": true
      },
      "cont": {
        "score": 65,
        "rating": "MODERATE",
        "display": "Moderate"
      },
      "catalyst": {
        "date": "2026-02-08",
        "date_display": "Feb 08, 2026",
        "event": "PDUFA",
        "drug": "RGX-121 (clemidsogene lanparvovec) - Hunter Syndrome (MPS II)",
        "days_to_catalyst": 15
      },
      "timing": {
        "days_to_expiry": 83,
        "entry_date": "2026-01-08 12:29:03"
      },
      "thesis": {
        "drug_name": "RGX-121 (clemidsogene lanparvovec) - Hunter Syndrome (MPS II)",
        "indication": "PDUFA",
        "highlights": [
          "RGNX presents a legitimate high-probability approval opportunity for RGX-121, a first-in-class gene therapy for Hunter syndrome. The regulatory pathway is clean: FDA inspections complete with zero observations, no safety concerns raised, and accelerated approval alignment. The PRV optionality provid..."
        ],
        "risks": [
          "No options meet 140% ENR threshold - paying 30-50% premium over fair value",
          "28% run-up suggests approval partially priced; limited upside vs. downside",
          "Denali competition (DNL310 PDUFA April 5) creates binary outcome for market share"
        ],
        "is_first_in_class": 1,
        "is_orphan": 1,
        "is_fast_track": 1,
        "short_interest": null
      },
      "oi": {
        "current": 0,
        "change_1d": 0,
        "change_5d": 0,
        "trend": "unknown"
      },
      "last_updated": "2026-01-23T20:35:49.363667"
    },
    {
      "ticker": "VNDA",
      "status": "OPEN",
      "play_type": "Standard",
      "is_phase3_sequential": false,
      "category": "Biotech",
      "position": {
        "strike": 6.0,
        "expiration": "2026-03-20",
        "expiration_display": "Mar 20, 2026",
        "option_type": "CALL",
        "quantity": 10
      },
      "prices": {
        "entry": 1.675,
        "current": 0.18,
        "stock_price": 7.3,
        "break_even": 7.675,
        "max_buy": 1.84,
        "pnl_pct": -89.3
      },
      "entry_zone": {
        "zone": "excellent",
        "color": "green",
        "message": "Down 89.3% from entry - better value",
        "pct_from_entry": -89.25373134328358
      },
      "enr": {
        "enr": 3273.2,
        "win_prob": 85.0,
        "enr_zone": {
          "zone": "good",
          "color": "green",
          "message": "Strong expected return"
        },
        "is_live": true
      },
      "cont": {
        "score": 72,
        "rating": "MODERATE",
        "display": "Moderate"
      },
      "catalyst": {
        "date": "2026-02-21",
        "date_display": "Feb 21, 2026",
        "event": "PDUFA",
        "drug": "Bysanti (milsaperidone) - Bipolar I & Schizophrenia (NEREUS approved 12/30/25)",
        "days_to_catalyst": 28
      },
      "timing": {
        "days_to_expiry": 55,
        "entry_date": "2025-12-31 07:15:00"
      },
      "thesis": {
        "drug_name": "Bysanti (milsaperidone) - Bipolar I & Schizophrenia (NEREUS approved 12/30/25)",
        "indication": "PDUFA",
        "highlights": [
          "VNDA presents a compelling multi-catalyst thesis for a 2026 LEAP: Bysanti PDUFA (Feb 21), imsidolimab PDUFA (~mid-2026), and NEREUS launch traction all captured in Dec 2026 expiration. The 1,931 OI at the $10 strike suggests institutional/retail conviction, and light insider buying is a rare positiv..."
        ],
        "risks": [
          "140% bid-ask spread makes entry/exit treacherous",
          "62% run-up means good news largely priced in",
          "Jan 7 HETLIOZ CRL shows FDA willing to reject Vanda applications"
        ],
        "is_first_in_class": 0,
        "is_orphan": 0,
        "is_fast_track": 0,
        "short_interest": 7.88
      },
      "oi": {
        "current": 0,
        "change_1d": 0,
        "change_5d": 0,
        "trend": "unknown"
      },
      "last_updated": "2026-01-23T20:35:49.407167"
    },
    {
      "ticker": "VNDA",
      "status": "OPEN",
      "play_type": "LEAP",
      "is_phase3_sequential": false,
      "category": "Biotech",
      "position": {
        "strike": 10.0,
        "expiration": "2026-12-18",
        "expiration_display": "Dec 18, 2026",
        "option_type": "CALL",
        "quantity": 30
      },
      "prices": {
        "entry": 1.95,
        "current": 0.060833333333333336,
        "stock_price": 7.3,
        "break_even": 11.95,
        "max_buy": 2.15,
        "pnl_pct": -96.9
      },
      "entry_zone": {
        "zone": "excellent",
        "color": "green",
        "message": "Down 96.9% from entry - better value",
        "pct_from_entry": -96.88034188034187
      },
      "enr": {
        "enr": 4288.9,
        "win_prob": 85.0,
        "enr_zone": {
          "zone": "good",
          "color": "green",
          "message": "Strong expected return"
        },
        "is_live": true
      },
      "cont": {
        "score": 72,
        "rating": "MODERATE",
        "display": "Moderate"
      },
      "catalyst": {
        "date": "2026-02-21",
        "date_display": "Feb 21, 2026",
        "event": "PDUFA",
        "drug": "Bysanti (milsaperidone) - Bipolar I & Schizophrenia (NEREUS approved 12/30/25)",
        "days_to_catalyst": 28
      },
      "timing": {
        "days_to_expiry": 328,
        "entry_date": "2026-01-07 10:23:15"
      },
      "thesis": {
        "drug_name": "Bysanti (milsaperidone) - Bipolar I & Schizophrenia (NEREUS approved 12/30/25)",
        "indication": "PDUFA",
        "highlights": [
          "VNDA presents a compelling multi-catalyst thesis for a 2026 LEAP: Bysanti PDUFA (Feb 21), imsidolimab PDUFA (~mid-2026), and NEREUS launch traction all captured in Dec 2026 expiration. The 1,931 OI at the $10 strike suggests institutional/retail conviction, and light insider buying is a rare positiv..."
        ],
        "risks": [
          "140% bid-ask spread makes entry/exit treacherous",
          "62% run-up means good news largely priced in",
          "Jan 7 HETLIOZ CRL shows FDA willing to reject Vanda applications"
        ],
        "is_first_in_class": 0,
        "is_orphan": 0,
        "is_fast_track": 0,
        "short_interest": 7.88
      },
      "oi": {
        "current": 0,
        "change_1d": 0,
        "change_5d": 0,
        "trend": "unknown"
      },
      "last_updated": "2026-01-23T20:35:49.443107"
    },
    {
      "ticker": "GOSS",
      "status": "OPEN",
      "play_type": "LEAP",
      "is_phase3_sequential": true,
      "category": "Biotech",
      "position": {
        "strike": 5.0,
        "expiration": "2027-01-15",
        "expiration_display": "Jan 15, 2027",
        "option_type": "CALL",
        "quantity": 60
      },
      "prices": {
        "entry": 1.15,
        "current": 0.017083333333333332,
        "stock_price": 2.5,
        "break_even": 6.15,
        "max_buy": 1.26,
        "pnl_pct": -98.5
      },
      "entry_zone": {
        "zone": "excellent",
        "color": "green",
        "message": "Down 98.5% from entry - better value",
        "pct_from_entry": -98.51449275362319
      },
      "enr": {
        "enr": 1951.8,
        "win_prob": 70.0,
        "enr_zone": {
          "zone": "good",
          "color": "green",
          "message": "Strong expected return"
        },
        "is_live": true
      },
      "cont": {
        "score": 60,
        "rating": "MODERATE",
        "display": "Moderate"
      },
      "catalyst": {
        "date": "2026-02-28",
        "date_display": "Feb 28, 2026",
        "event": "Phase 3",
        "drug": "Seralutinib - Pulmonary Arterial Hypertension (PAH) - PROSERA Trial",
        "days_to_catalyst": 35
      },
      "timing": {
        "days_to_expiry": 356,
        "entry_date": "2025-12-31 07:14:59"
      },
      "thesis": {
        "drug_name": "Seralutinib - Pulmonary Arterial Hypertension (PAH) - PROSERA Trial",
        "indication": "Phase 3",
        "highlights": [
          "GOSS presents a compelling contrarian LEAP opportunity with institutional validation via the concentrated 4,339 OI on the $3 Jan-2027 strike. The structural setup is textbook: proven management (Hasnain sold Receptos for $7.2B), heavy insider buying at $1.14-$1.82, first-in-class mechanism with comb..."
        ],
        "risks": [
          "Phase 2 TORREY missed 6MWD endpoint - same endpoint used in Phase 3 PROSERA",
          "Merck Winrevair first-mover advantage in PAH market with $238K/year pricing",
          "Enriched FC II/III patient strategy relies on subgroup signal that may not replicate"
        ],
        "is_first_in_class": 1,
        "is_orphan": 1,
        "is_fast_track": 0,
        "short_interest": 3.6
      },
      "oi": {
        "current": 0,
        "change_1d": 0,
        "change_5d": 0,
        "trend": "unknown"
      },
      "last_updated": "2026-01-23T20:35:49.483120"
    },
    {
      "ticker": "GOSS",
      "status": "OPEN",
      "play_type": "LEAP",
      "is_phase3_sequential": true,
      "category": "Biotech",
      "position": {
        "strike": 3.0,
        "expiration": "2027-01-15",
        "expiration_display": "Jan 15, 2027",
        "option_type": "CALL",
        "quantity": 50
      },
      "prices": {
        "entry": 1.4,
        "current": 0.023,
        "stock_price": 2.5,
        "break_even": 4.4,
        "max_buy": 1.54,
        "pnl_pct": -98.4
      },
      "entry_zone": {
        "zone": "excellent",
        "color": "green",
        "message": "Down 98.4% from entry - better value",
        "pct_from_entry": -98.35714285714286
      },
      "enr": {
        "enr": 7511.7,
        "win_prob": 70.0,
        "enr_zone": {
          "zone": "good",
          "color": "green",
          "message": "Strong expected return"
        },
        "is_live": true
      },
      "cont": {
        "score": 60,
        "rating": "MODERATE",
        "display": "Moderate"
      },
      "catalyst": {
        "date": "2026-02-28",
        "date_display": "Feb 28, 2026",
        "event": "Phase 3",
        "drug": "Seralutinib - Pulmonary Arterial Hypertension (PAH) - PROSERA Trial",
        "days_to_catalyst": 35
      },
      "timing": {
        "days_to_expiry": 356,
        "entry_date": "2026-01-07 13:19:27"
      },
      "thesis": {
        "drug_name": "Seralutinib - Pulmonary Arterial Hypertension (PAH) - PROSERA Trial",
        "indication": "Phase 3",
        "highlights": [
          "GOSS presents a compelling contrarian LEAP opportunity with institutional validation via the concentrated 4,339 OI on the $3 Jan-2027 strike. The structural setup is textbook: proven management (Hasnain sold Receptos for $7.2B), heavy insider buying at $1.14-$1.82, first-in-class mechanism with comb..."
        ],
        "risks": [
          "Phase 2 TORREY missed 6MWD endpoint - same endpoint used in Phase 3 PROSERA",
          "Merck Winrevair first-mover advantage in PAH market with $238K/year pricing",
          "Enriched FC II/III patient strategy relies on subgroup signal that may not replicate"
        ],
        "is_first_in_class": 1,
        "is_orphan": 1,
        "is_fast_track": 0,
        "short_interest": 3.6
      },
      "oi": {
        "current": 0,
        "change_1d": 0,
        "change_5d": 0,
        "trend": "unknown"
      },
      "last_updated": "2026-01-23T20:35:49.516785"
    },
    {
      "ticker": "IMMP",
      "status": "OPEN",
      "play_type": "Standard",
      "is_phase3_sequential": false,
      "category": "Biotech",
      "position": {
        "strike": 2.5,
        "expiration": "2026-07-17",
        "expiration_display": "Jul 17, 2026",
        "option_type": "CALL",
        "quantity": 30
      },
      "prices": {
        "entry": 0.9,
        "current": 0.9,
        "stock_price": 0,
        "break_even": 3.4,
        "max_buy": 0.99,
        "pnl_pct": 0.0
      },
      "entry_zone": {
        "zone": "good",
        "color": "green",
        "message": "Within 0.0% of entry - still good",
        "pct_from_entry": 0.0
      },
      "enr": {
        "enr": 0,
        "win_prob": 0,
        "enr_zone": {
          "zone": "avoid",
          "color": "red",
          "message": "Negative expected return"
        },
        "is_live": false
      },
      "cont": {
        "score": 55,
        "rating": "MODERATE",
        "display": "Moderate"
      },
      "catalyst": {
        "date": "2026-03-31",
        "date_display": "Mar 31, 2026",
        "event": "Phase 3 Data readout",
        "drug": null,
        "days_to_catalyst": 66
      },
      "timing": {
        "days_to_expiry": 174,
        "entry_date": "2026-01-21"
      },
      "thesis": {
        "drug_name": null,
        "indication": "Phase 3 Data readout",
        "highlights": [
          "IMMP presents a compelling long-term biotech investment case - the Phase 2 INSIGHT-003 data showing 32.9-month mOS vs 22.0-month historical benchmark is genuinely impressive, the Dr. Reddy's $369M total deal value validates the asset, and efti's differentiated MHC Class II mechanism is scientificall..."
        ],
        "risks": [
          "Catalyst date is FUTILITY ANALYSIS Q1 2026, NOT Phase 3 efficacy data",
          "All available options have >30% spreads = untradeable",
          "84% run-up suggests options premium already inflated"
        ],
        "is_first_in_class": 1,
        "is_orphan": 0,
        "is_fast_track": 1,
        "short_interest": 3.59
      },
      "oi": {
        "current": 0,
        "change_1d": 0,
        "change_5d": 0,
        "trend": "unknown"
      },
      "last_updated": "2026-01-23T20:35:49.556118"
    },
    {
      "ticker": "MNKD",
      "status": "OPEN",
      "play_type": "LEAP",
      "is_phase3_sequential": false,
      "category": "Biotech",
      "position": {
        "strike": 7.0,
        "expiration": "2027-01-15",
        "expiration_display": "Jan 15, 2027",
        "option_type": "CALL",
        "quantity": 80
      },
      "prices": {
        "entry": 1.2,
        "current": 0.0165625,
        "stock_price": 5.8544,
        "break_even": 8.2,
        "max_buy": 1.32,
        "pnl_pct": -98.6
      },
      "entry_zone": {
        "zone": "excellent",
        "color": "green",
        "message": "Down 98.6% from entry - better value",
        "pct_from_entry": -98.61979166666667
      },
      "enr": {
        "enr": 19125.9,
        "win_prob": 90.0,
        "enr_zone": {
          "zone": "good",
          "color": "green",
          "message": "Strong expected return"
        },
        "is_live": true
      },
      "cont": {
        "score": 75,
        "rating": "MODERATE",
        "display": "Moderate"
      },
      "catalyst": {
        "date": "2026-05-29",
        "date_display": "May 29, 2026",
        "event": "PDUFA",
        "drug": "Afrezza (insulin human) - Dose Conversion Label Update",
        "days_to_catalyst": 125
      },
      "timing": {
        "days_to_expiry": 356,
        "entry_date": "2025-12-31 07:14:55"
      },
      "thesis": {
        "drug_name": "Afrezza (insulin human) - Dose Conversion Label Update",
        "indication": "PDUFA",
        "highlights": [
          "MNKD presents a novel dual-PDUFA catalyst setup with back-to-back approval decisions in May and July 2026. The massive open interest (4,374 contracts on $10 strike alone) suggests institutional positioning, which is intriguing. However, this fundamentally differs from high-ENR binary plays because b..."
        ],
        "risks": [
          "Label expansions rarely drive 50%+ moves - may be priced in",
          "Management selling, not buying their own stock",
          "MNKD-101 failure removed key pipeline catalyst"
        ],
        "is_first_in_class": 1,
        "is_orphan": 0,
        "is_fast_track": 0,
        "short_interest": 8.6
      },
      "oi": {
        "current": 0,
        "change_1d": 0,
        "change_5d": 0,
        "trend": "unknown"
      },
      "last_updated": "2026-01-23T20:35:49.594673"
    },
    {
      "ticker": "ACHV",
      "status": "OPEN",
      "play_type": "LEAP",
      "is_phase3_sequential": false,
      "category": "Biotech",
      "position": {
        "strike": 5.0,
        "expiration": "2026-12-18",
        "expiration_display": "Dec 18, 2026",
        "option_type": "CALL",
        "quantity": 30
      },
      "prices": {
        "entry": 2.25,
        "current": 0.07583333333333334,
        "stock_price": 5.429,
        "break_even": 7.25,
        "max_buy": 2.48,
        "pnl_pct": -96.6
      },
      "entry_zone": {
        "zone": "excellent",
        "color": "green",
        "message": "Down 96.6% from entry - better value",
        "pct_from_entry": -96.62962962962963
      },
      "enr": {
        "enr": 5878.9,
        "win_prob": 95.0,
        "enr_zone": {
          "zone": "good",
          "color": "green",
          "message": "Strong expected return"
        },
        "is_live": true
      },
      "cont": {
        "score": 45,
        "rating": "LOW",
        "display": "Low (Exit Early)"
      },
      "catalyst": {
        "date": "2026-06-20",
        "date_display": "Jun 20, 2026",
        "event": "PDUFA Approval decision",
        "drug": "Cytisinicline - Smoking Cessation (Nicotine Dependence)",
        "days_to_catalyst": 147
      },
      "timing": {
        "days_to_expiry": 328,
        "entry_date": "2026-01-08 12:29:02"
      },
      "thesis": {
        "drug_name": "Cytisinicline - Smoking Cessation (Nicotine Dependence)",
        "indication": "PDUFA Approval decision",
        "highlights": [
          "ACHV has a genuinely strong fundamental setup: two successful Phase 3 trials, Breakthrough Therapy designation, clean safety profile, and a real unmet need (first new smoking cessation drug in 20 years). The PDUFA date of June 20, 2026 is verified across multiple company press releases and FDA commu..."
        ],
        "risks": [
          "Highlighted option expires 2 days BEFORE PDUFA date - cannot capture catalyst",
          "Generic varenicline competition limits commercial upside",
          "Tight cash runway with likely dilution before/after approval"
        ],
        "is_first_in_class": 1,
        "is_orphan": 0,
        "is_fast_track": 0,
        "short_interest": null
      },
      "oi": {
        "current": 0,
        "change_1d": 0,
        "change_5d": 0,
        "trend": "unknown"
      },
      "last_updated": "2026-01-23T20:35:49.647022"
    },
    {
      "ticker": "CRMD",
      "status": "OPEN",
      "play_type": "LEAP",
      "is_phase3_sequential": true,
      "category": "Biotech",
      "position": {
        "strike": 8.0,
        "expiration": "2026-08-21",
        "expiration_display": "Aug 21, 2026",
        "option_type": "CALL",
        "quantity": 40
      },
      "prices": {
        "entry": 1.4,
        "current": 1.4,
        "stock_price": 0,
        "break_even": 9.4,
        "max_buy": 1.54,
        "pnl_pct": 0.0
      },
      "entry_zone": {
        "zone": "good",
        "color": "green",
        "message": "Within 0.0% of entry - still good",
        "pct_from_entry": 0.0
      },
      "enr": {
        "enr": 0,
        "win_prob": 0,
        "enr_zone": {
          "zone": "avoid",
          "color": "red",
          "message": "Negative expected return"
        },
        "is_live": false
      },
      "cont": {
        "score": 90,
        "rating": "HIGH",
        "display": "High (Hold Through)"
      },
      "catalyst": {
        "date": "2026-06-30",
        "date_display": "Jun 30, 2026",
        "event": "Phase 3 Data readout",
        "drug": null,
        "days_to_catalyst": 157
      },
      "timing": {
        "days_to_expiry": 209,
        "entry_date": "2026-01-21"
      },
      "thesis": {
        "drug_name": null,
        "indication": "Phase 3 Data readout",
        "highlights": [],
        "risks": [],
        "is_first_in_class": 0,
        "is_orphan": 1,
        "is_fast_track": 1,
        "short_interest": 21.63
      },
      "oi": {
        "current": 0,
        "change_1d": 0,
        "change_5d": 0,
        "trend": "unknown"
      },
      "last_updated": "2026-01-23T20:35:49.696715"
    }
  ],
  "summary": {
    "total_positions": 11,
    "total_value": 11020.0,
    "avg_days_to_catalyst": 56.0
  },
  "market_status": {
    "is_open": true,
    "last_updated": "2026-01-23T20:35:49.696797"
  },
  "last_updated": "2026-01-23T20:35:49.696801"
}